SCHEDULE: ResMed Inc. Discloses Nyxoah SA Stake

ResMed Inc. has filed a Schedule 13G, reporting beneficial ownership of 1,943,828 ordinary shares in Nyxoah SA, representing 1.95% of the outstanding shares.

Summary

• ResMed Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Nyxoah SA ordinary shares.
• As of June 30, 2026, ResMed Inc. beneficially owns 1,943,828 ordinary shares of Nyxoah SA.
• This holding represents 1.95% of the total outstanding ordinary shares of Nyxoah SA, based on 99,926,284 shares outstanding as of June 10, 2026.
• ResMed Inc. has sole voting power and sole dispositive power over these shares.
• The filing indicates that these securities were not acquired or are not held for the purpose of or with the effect of changing or influencing the control of Nyxoah SA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership without any new strategic announcements or significant changes in holdings that would immediately impact market perception.

Positives

• ResMed Inc. has a significant, though not controlling, stake in Nyxoah SA, indicating potential strategic interest or investment.
• The filing is an amendment, suggesting ongoing monitoring and reporting of shareholdings.

Risks

• The filing does not detail specific risks associated with this investment, but any investment carries inherent market and company-specific risks.
• A significant stake could imply potential future involvement or influence, which may carry associated governance or strategic risks for ResMed Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future shareholdings or strategic plans related to Nyxoah SA.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by ResMed Inc. regarding Nyxoah SA is a routine disclosure for significant institutional investors. It indicates ResMed's passive investment in a company within a related or complementary sector, without immediate implications for control or active influence, which is common in the medical device and healthcare technology industries.

Stakeholder Impact

• Shareholders of ResMed Inc.: The investment represents a small portion of ResMed's overall portfolio, with minimal direct impact unless the value of Nyxoah SA shares fluctuates significantly.
• Shareholders of Nyxoah SA: The filing confirms ResMed Inc. as a significant passive shareholder, which may be viewed positively by some investors as a sign of institutional interest, but does not imply active support or control.
• Regulators (SEC): Compliance with reporting requirements under the Securities Exchange Act of 1934 is maintained.

Next Steps

• ResMed Inc. will continue to monitor its shareholding in Nyxoah SA and file amendments to Schedule 13G as required by regulations.
• Nyxoah SA will continue its operations and reporting as a public company.

Key Dates

Keywords

Schedule 13G, ResMed Inc., Nyxoah SA, Beneficial Ownership, Ordinary Shares, SEC Filing, Investment, Securities Exchange Act